TITLE

Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial

AUTHOR(S)
Adinolfi, L.E.; Utili, R.; Tonziello, A.; Ruggiero, G.
PUB. DATE
May 2003
SOURCE
Gut;May2003, Vol. 52 Issue 5, p701
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Fifty per cent of chronic hepatitis C patients are non-responders to interferon. At present, there are no recommended therapeutic options for non- responders. Aims: The safety and long term effect of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non- responsive chronic hepatitis C was evaluated. Patients and methods: A total of 114 consecutive patients were randomly divided into three groups with a final 2:2:1 ratio: group A (44 patients) received interferon alfa 2b, 3 million units (MU), three times a week, and oral ribavirin (1000 mg/day); group B (46 patients) received interferon 3 MU daily for the first four weeks and subsequently 3 MU three times a week, and ribavirin as in regimen A; and group C (24 patients) received interferon and ribavirin as in regimen B, plus oral amantadine hydrochloride (200 mg/day). The duration of treatment was 12 months. Results: The end of treatment response for groups A and B was 25% and 29%, respectively, and for group C, 68% (p<0.005). At the end of one year of follow up, a sustained response was observed for six (25%) patients in group C, one (2%) patient in group A, and two (4%) patients in group B (p<0.002). The triple regimen was well tolerated and did not increase the frequency or severity of side effects. Conclusions: The study demonstrates that for the treatment of interferon non-responder hepatitis C patients, the association of interferon-ribavirin has a negligible long term effect whereas a triple regimen including interferon, ribavirin, and amantadine can be an effective and safe treatment.
ACCESSION #
9737025

 

Related Articles

  • Interferon affacon-1.  // Formulary;May2005, Vol. 40 Issue 5, p168 

    Reports on successful retreatment of chronic hepatitis C patients with a nonresponse to standard interferon/ribavirin using daily consensus interferon and ribavirin.

  • Modifications of the Immune Responsiveness in Patients with Hepatitis C Virus Infection following Treatment with IFN-a / Ribavirin. Caradonna, L.; Mastronardi, M.L.; Amati, L.; Magrone, T.; Cuppone, R.; Cozzolongo, R.; Manghisi, O.G.; Caccavo, D.; Amoroso, A.; Jirillo, E. // Current Pharmaceutical Design;May2002, Vol. 8 Issue 11, p981 

    The balance between T helper (h)1 and Th2 responsiveness seems to represent a key event in the evolution of hepatitis C virus (HCV) infection. In particular, Th1 cytokines [interleukin (IL-2) and interferon (IFN-?)] have been demonstrated to mediate the antiviral immune response. Serum levels of...

  • Therapy of Chronic Hepatitis C: A Critical Review. Saracco, G.; Olivero, A.; Ciancio, A.; Carenzi, S.; Rizzetto, M. // Current Drug Targets - Infectious Disorders;Mar2003, Vol. 3 Issue 1, p25 

    Combination therapy (Interferon plus ribavirin) is the current therapeutic gold standard for naive Hepatitis C Virus (HCV)-positive patients and with the recent advent of pegylated (PEG) IFN the rate of the sustained virological response (HCV-RNA clearance 6 months after the end of treatment) is...

  • Interferon-α Alone versus Interferon-α plus Ribavirin in Patients with Chronic Hepatitis C Not Responding to Previous Interferon-α Treatment. Tripi, S.; Di Gaetano, G.; Soresi, M.; Cartabellotta, F.; Vassallo, R.; Carroccio, A.; Anastasi, G.; Montalto, G. // BioDrugs;2000, Vol. 13 Issue 4, p299 

    Objective: To study the effects of monotherapy with leucocyte interferon-α (IFNα) versus IFNα + ribavirin in patients with chronic hepatitis C who were nonresponders to previous courses of recombinant or lymphoblastoid IFNα. Design and setting: This was a nonblind randomised study of...

  • Optimizing Ribavirin Exposure by Therapeutic Drug Monitoring Improves Treatment Response in Patients With Chronic Hepatitis C Genotype 1. Stickel, Felix; Worni, Mathias; Pache, Isabelle; Moradpour, Darius; Helbling, Beat; Borovicka, Jan; Gerlach, Tilman J // American Journal of Gastroenterology;Jul2013, Vol. 108 Issue 7, p1176 

    A letter to the editor is presented in response to the article "Optimum Ribavirin Exposure Overcomes Racial Disparity in Efficacy of Peginterferon and Ribavirin Treatment for Hepatitis C Genotype 1" by R. Jin and colleagues in the 2012 issue.

  • Triple Therapy for Hepatitis C Virus Infection in Patients Receiving Hemodialysis. Lemoinne, Sara; Barrou, Benoit; Thabut, Dominique // Annals of Internal Medicine;4/15/2014, Vol. 160 Issue 8, p581 

    A letter to the editor is presented in response to the article "Pegylated interferon-É‘2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis:a randomized trial" by C.H. Liu and others in a 2013 issue along with the response.

  • Combination Therapy with Interferon-α and Ribavirin for Hepatitis C: Practical Treatment Issues. Collier, J.; Chapman, R. // BioDrugs;2001, Vol. 15 Issue 4, p225 

    Combination therapy with ribavirin and interferon (IFN)-α for 6 to 12 months is currently the treatment of choice for chronic hepatitis C infection. The overall sustained response rate to treatment, defined as loss of hepatitis C virus (HCV) from serum 6 months after completion of treatment,...

  • Two-pronged attack on hepatitis C.  // Consumer Reports on Health;Apr99, Vol. 11 Issue 4, p6 

    Reports on findings on the effectiveness of using interferon injections with the oral antiviral drug ribavirin to treat hepatitis C, as published in `The New England Journal of Medicine.'

  • An evaluation of interferon in the treatment of hepatitis C virus infection. Guay, David R.P. // Formulary;Feb99, Vol. 34 Issue 2, p132 

    Assesses the efficacy and side effect profiles of interferon (IFN) with or without ribavirin in the treatment of hepatitis C virus (HCV)-infected patients in the United States. Serologic testing; Focus of therapy; Reduction of the biologic and virologic markers of HCV infection; Sustained...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics